Screening for Prostate Cancer Among Those Prostate-specific Antigen Value Between 2.5 and 4.0 ng/mL
Screening for Prostate Cancer Among Those Prostate-specific Antigen Value Between 2.5 and 4.0 ng/mL
The study aims to evaluate the detection rate and characteristics of prostate cancer among
 males with PSA values between 2.5 and 4.0 ng/mL in Nanjing, meanwhile, to access the
 effectiveness of conducting multi-parametric MRI (mpMRI) after PSA assay.
The investigators are going to collect serum samples and clinical information from men aged
 ≥50 years in community health service centers in Nanjing. The investigators will propose
 mpMRI for those met our criteria of PSA values between 2.5 and 4.0 ng/ml. Transperineal
 systematic biopsy and MRI/ultrasound fusion targeted biopsy will be offered for those who
 scored ≥3 points on the Prostate Imaging-Reporting and Data System Version 2 (PI-RADS v2).
 Follow-up examinations annually will be offered for those with a PI-RADS score <3. Sequences
 obtained while conducting mpMRI included T2-weighted imaging, diffusion-weighted imaging, and
 dynamic contrast-enhanced using a 3.0-T system.
Inclusion Criteria:

 -  Age ≥ 50

 -  PSA between 2.5 and 4.0ng/ml

 -  (Eastern Cooperative Oncology Group)ECOG grade: 0-1

 -  Normal organic function indexes:

 -  (absolute neutrophil count)ANC ≧1.5×109/L

 -  (platelet count)PLT ≧100×109/L

 -  Hb ≧90 g/L

 -  (total bilirubin)TBIL ≦1.5×ULN

 -  (aspartate aminotransferase)ALT≦2.5×ULN

 -  (alanine aminotransferase)AST ≦2.5×ULN

 -  (blood urea nitrogen)BUN (orUREA) and Cr ≦1.5×ULN

 Exclusion Criteria:

 -  Former serum PSA detection

 -  Having took Proscar in the past 3 months

 -  Suffered from any other malignant tumor in the past 5 years

 -  History of acute urinary retention, acute or chronic bacterial or abacterial
 prostatitis within 6 weeks or other recent infection of the urinary system